A 50-year-old man with severe obstructive sleep apnea (AHI 65 events/hour) and CPAP intolerance despite multiple mask trials undergoes maxillomandibular advancement surgery. Three months post-operatively, he continues to report excessive daytime sleepiness and his bed partner reports persistent snoring. Post-operative polysomnography shows AHI of 28 events/hour. He has a BMI of 38 kg/m² (unchanged from pre-surgery) and crowded posterior pharynx. Evaluate the next management strategy.
Q2
A 70-year-old man with newly diagnosed Parkinson disease and REM sleep behavior disorder is being considered for treatment. His neurologist is concerned about medication interactions and disease progression. He also has mild cognitive impairment, orthostatic hypotension, and a history of visual hallucinations. Evaluate the optimal therapeutic approach considering his complex medical profile.
Q3
A 25-year-old medical resident presents with excessive daytime sleepiness and difficulty maintaining wakefulness during lectures. Polysomnography shows normal sleep architecture with a sleep latency of 8 minutes. Multiple Sleep Latency Test (MSLT) shows a mean sleep latency of 4 minutes with 1 sleep-onset REM period (SOREMP). She works rotating shifts, sleeps 4-5 hours on workdays, and has no cataplexy. Evaluation of this clinical scenario suggests which diagnosis best accounts for all findings?
Q4
A 40-year-old woman presents with chronic insomnia, taking zolpidem 10 mg nightly for 2 years. Despite medication, she reports difficulty falling asleep, frequent awakenings, and spends significant time in bed worrying about sleep. She naps for 2-3 hours in the afternoon and has an irregular sleep schedule. Her bedroom has a television that she watches until falling asleep. Analysis of perpetuating factors suggests which intervention addresses the core maintaining mechanism of her insomnia?
Q5
A 55-year-old obese man with treatment-resistant hypertension, type 2 diabetes, and atrial fibrillation undergoes polysomnography which reveals an apnea-hypopnea index (AHI) of 45 events/hour with oxygen desaturations to 78%. He is started on CPAP therapy but returns 3 months later with improved sleep but persistent hypertension despite four antihypertensive medications. Analysis of the relationship between his conditions suggests which mechanism best explains the treatment resistance?
Sleep disorders US Medical PG Practice Questions and MCQs
Question 1: A 50-year-old man with severe obstructive sleep apnea (AHI 65 events/hour) and CPAP intolerance despite multiple mask trials undergoes maxillomandibular advancement surgery. Three months post-operatively, he continues to report excessive daytime sleepiness and his bed partner reports persistent snoring. Post-operative polysomnography shows AHI of 28 events/hour. He has a BMI of 38 kg/m² (unchanged from pre-surgery) and crowded posterior pharynx. Evaluate the next management strategy.
A. Hypoglossal nerve stimulation therapy evaluation
B. Repeat maxillomandibular advancement with greater advancement distance
C. Observe for another 3 months as surgical swelling may still be resolving
D. Revisit CPAP therapy with auto-adjusting pressure settings (Correct Answer)
E. Proceed directly to tracheostomy for definitive airway management
Explanation: ***Revisit CPAP therapy with auto-adjusting pressure settings***
- **Maxillomandibular advancement (MMA)** significantly reduced the **Apnea-Hypopnea Index (AHI)** from 65 to 28; while not curative, this anatomical change may lower the **positive airway pressure (PAP)** requirements, potentially improving **patient tolerance**.
- **Auto-CPAP** is the most appropriate next step to determine if the post-surgical airway allows for successful treatment at manageable pressures, especially before considering more invasive options.
*Hypoglossal nerve stimulation therapy evaluation*
- This patient's **BMI of 38 kg/m²** currently exceeds the standard FDA-approved threshold of **35 kg/m²** for **hypoglossal nerve stimulation**.
- Evaluation requires a **Drug-Induced Sleep Endoscopy (DISE)** to check for **concentric palatal collapse**, but primary medical optimization remains the priority.
*Repeat maxillomandibular advancement with greater advancement distance*
- **Revision MMA** carries significantly higher surgical risks, including **nerve injury** and **non-union**, and is generally not indicated when initial surgery was technically successful.
- The persistent **AHI of 28** is more likely due to the patient's **persistent obesity** and soft tissue volume rather than inadequate bony advancement.
*Observe for another 3 months as surgical swelling may still be resolving*
- Three months is typically sufficient for the resolution of **post-operative edema** impacting the airway, and active treatment is needed for **moderate OSA** (AHI 28) and **daytime sleepiness**.
- Delaying management puts the patient at continued risk for **cardiovascular complications** and accidents associated with **excessive sleepiness**.
*Proceed directly to tracheostomy for definitive airway management*
- **Tracheostomy** is the most invasive surgical intervention and is reserved for **life-threatening OSA** where all other medical and surgical options have failed.
- It represents a significant **quality-of-life burden** and should not be considered until less invasive modalities like post-surgical **PAP therapy** are re-attempted.
Question 2: A 70-year-old man with newly diagnosed Parkinson disease and REM sleep behavior disorder is being considered for treatment. His neurologist is concerned about medication interactions and disease progression. He also has mild cognitive impairment, orthostatic hypotension, and a history of visual hallucinations. Evaluate the optimal therapeutic approach considering his complex medical profile.
A. Quetiapine for both hallucinations and RBD symptoms
B. Clonazepam 0.5 mg at bedtime with close monitoring for falls
C. Rivastigmine to address cognitive impairment and sleep disturbance
D. Melatonin 3-12 mg at bedtime as first-line therapy (Correct Answer)
E. Pramipexole dose adjustment to suppress REM sleep
Explanation: ***Melatonin 3-12 mg at bedtime as first-line therapy***
- **Melatonin** is the preferred first-line treatment for **REM sleep behavior disorder (RBD)** in elderly patients with neurodegeneration due to its excellent safety profile.
- It effectively reduces **dream enactment** with a lower risk of side effects like **excessive sedation** or motor instability compared to other agents.
*Quetiapine for both hallucinations and RBD symptoms*
- While **Quetiapine** is used to manage **visual hallucinations** in Parkinson's, it is not an established or effective therapy for managing **RBD symptoms**.
- It may worsen **orthostatic hypotension** and daytime somnolence, complicating the patient's existing clinical state.
*Clonazepam 0.5 mg at bedtime with close monitoring for falls*
- **Clonazepam** is highly effective for RBD but is generally avoided in patients with **mild cognitive impairment** and **orthostatic hypotension** due to the high risk of **confusion** and **falls**.
- It can also exacerbate **obstructive sleep apnea** or cause significant **morning-after sedation** in the elderly.
*Rivastigmine to address cognitive impairment and sleep disturbance*
- **Rivastigmine**, a cholinesterase inhibitor, is used for **Parkinson disease dementia** but is not the primary treatment for **REM sleep behavior disorder**.
- Although it may help cognitive symptoms, it does not reliably suppress the physical **dream enactment** characteristic of RBD.
*Pramipexole dose adjustment to suppress REM sleep*
- **Dopamine agonists** like **Pramipexole** are known to potentially **worsen RBD** and can significantly increase the frequency of **visual hallucinations**.
- Increasing the dose in this patient would likely exacerbate his **psychosis** and **orthostatic hypotension**.
Question 3: A 25-year-old medical resident presents with excessive daytime sleepiness and difficulty maintaining wakefulness during lectures. Polysomnography shows normal sleep architecture with a sleep latency of 8 minutes. Multiple Sleep Latency Test (MSLT) shows a mean sleep latency of 4 minutes with 1 sleep-onset REM period (SOREMP). She works rotating shifts, sleeps 4-5 hours on workdays, and has no cataplexy. Evaluation of this clinical scenario suggests which diagnosis best accounts for all findings?
A. Idiopathic hypersomnia with long sleep time
B. Narcolepsy type 1 requiring CSF hypocretin measurement
C. Shift work sleep disorder with circadian misalignment
D. Narcolepsy type 2 based on objective sleepiness and one SOREMP
E. Insufficient sleep syndrome related to work schedule (Correct Answer)
Explanation: ***Insufficient sleep syndrome related to work schedule***
- The patient reports sleeping only **4-5 hours** on workdays, which represents chronic **sleep restriction** compared to the physiological requirement of 7-9 hours.
- **Chronic sleep deprivation** can lead to a shortened mean sleep latency of <8 minutes and single **SOREMPs** on MSLT, making it the most plausible explanation for the findings in a medical resident.
*Idiopathic hypersomnia with long sleep time*
- This condition is characterized by a mean sleep latency of <8 minutes but typically involves **prolonged sleep episodes** (more than 10-11 hours) with significant **sleep drunkenness**.
- The diagnosis requires ruling out **insufficient sleep**, and this patient’s restricted 4-5 hour sleep window directly contradicts the "long sleep time" criteria.
*Narcolepsy type 1 requiring CSF hypocretin measurement*
- **Narcolepsy Type 1** requires the presence of **cataplexy** or low **CSF hypocretin-1** levels, neither of which is suggested by the patient's history.
- The MSLT results in this case only showed **one SOREMP**, whereas Narcolepsy Type 1 diagnosis usually requires **two or more SOREMPs** (or one SOREMP during polysomnography and one during MSLT).
*Shift work sleep disorder with circadian misalignment*
- While the patient works rotating shifts, this disorder specifically involves insomnia or sleepiness that is temporally linked to the **work schedule** causing **circadian misalignment**.
- The primary issue here is the **quantity of sleep** (4-5 hours) rather than the timing of sleep relative to her internal clock, pointing more specifically to insufficient sleep syndrome.
*Narcolepsy type 2 based on objective sleepiness and one SOREMP*
- Diagnostic criteria for **Narcolepsy Type 2** require a mean sleep latency of ≤8 minutes and **two or more SOREMPs**; this patient only had one SOREMP.
- A diagnosis of Narcolepsy Type 2 cannot be made until **insufficient sleep syndrome** is ruled out by ensuring adequate sleep hygiene for at least two weeks prior to testing.
Question 4: A 40-year-old woman presents with chronic insomnia, taking zolpidem 10 mg nightly for 2 years. Despite medication, she reports difficulty falling asleep, frequent awakenings, and spends significant time in bed worrying about sleep. She naps for 2-3 hours in the afternoon and has an irregular sleep schedule. Her bedroom has a television that she watches until falling asleep. Analysis of perpetuating factors suggests which intervention addresses the core maintaining mechanism of her insomnia?
A. Polysomnography to identify underlying sleep architecture abnormalities
B. Switching to a longer-acting benzodiazepine receptor agonist
C. Gradual tapering of zolpidem with substitution of melatonin
D. Cognitive behavioral therapy for insomnia (CBT-I) with sleep restriction (Correct Answer)
E. Adding a sedating antidepressant to the current regimen
Explanation: ***Cognitive behavioral therapy for insomnia (CBT-I) with sleep restriction***
- This patient exhibits **maladaptive behaviors** such as excessive time in bed, afternoon napping, and conditioned arousal (watching TV in bed) that perpetuate chronic insomnia.
- **CBT-I** is the first-line treatment as it uses **sleep restriction** and **stimulus control** to consolidate sleep and address the underlying cognitive distortions regarding sleep.
*Polysomnography to identify underlying sleep architecture abnormalities*
- **Polysomnography** is generally not indicated for the diagnosis of chronic insomnia unless a breathing disorder or **periodic limb movement disorder** is suspected.
- It does not address the **perpetuating behavioral factors** such as napping and irregular schedules identified in this patient.
*Switching to a longer-acting benzodiazepine receptor agonist*
- Switching to long-acting agents increases the risk of **daytime sedation**, falls, and cognitive impairment without addressing behavioral causes.
- This does not target the **conditioned arousal** or poor sleep hygiene that are maintaining the patient's insomnia.
*Gradual tapering of zolpidem with substitution of melatonin*
- While tapering is often necessary, **melatonin** has limited efficacy for chronic insomnia and does not address the core behavioral issues like excessive time in bed.
- It fails to provide the **cognitive restructuring** needed to manage the patient's anxiety about falling asleep.
*Adding a sedating antidepressant to the current regimen*
- Adding more medication leads to **polypharmacy** and fails to treat the root cause, which is behavioral and cognitive in nature.
- Sedating antidepressants do not improve **sleep efficiency** or consolidate the sleep cycle as effectively as behavioral interventions.
Question 5: A 55-year-old obese man with treatment-resistant hypertension, type 2 diabetes, and atrial fibrillation undergoes polysomnography which reveals an apnea-hypopnea index (AHI) of 45 events/hour with oxygen desaturations to 78%. He is started on CPAP therapy but returns 3 months later with improved sleep but persistent hypertension despite four antihypertensive medications. Analysis of the relationship between his conditions suggests which mechanism best explains the treatment resistance?
A. Poor CPAP adherence with inadequate resolution of nocturnal hypoxemia (Correct Answer)
B. CPAP therapy requires 6-12 months to impact blood pressure
C. Concurrent primary hyperaldosteronism is the cause of both conditions
D. Intermittent hypoxia has caused irreversible sympathetic nervous system activation
E. Aldosterone excess from obstructive sleep apnea persists despite CPAP
Explanation: ***Poor CPAP adherence with inadequate resolution of nocturnal hypoxemia***
- The most common reason for **persistent hypertension** despite starting **CPAP** is inadequate device adherence, as clinically significant BP reduction requires at least 4-6 hours of use per night.
- Ongoing **nocturnal hypoxemia** due to poor adherence continues to drive **sympathetic nervous system** overactivity, preventing the stabilization of blood pressure levels.
*CPAP therapy requires 6-12 months to impact blood pressure*
- Significant physiological improvements in **hemodynamics** and reductions in **blood pressure** are typically observed within weeks to 3 months of effective, consistent **CPAP** use.
- Waiting 6-12 months for an initial response is inconsistent with clinical guidelines for assessing **treatment-resistant hypertension**.
*Concurrent primary hyperaldosteronism is the cause of both conditions*
- While **primary hyperaldosteronism** is a cause of resistant hypertension, it does not cause **obstructive sleep apnea (OSA)** directly; rather, **OSA** can cause secondary elevations in **aldosterone**.
- There is no clinical evidence in the stem, such as **hypokalemia**, to specifically prioritize this diagnosis over treatment non-adherence.
*Intermittent hypoxia has caused irreversible sympathetic nervous system activation*
- Although chronic **OSA** causes neural remodeling, the **sympathetic activation** is largely reversible or at least modifiable with high-quality, continuous treatment.
- Labeling the activation as **irreversible** at this stage is medically incorrect, as blood pressure usually improves once **apneic events** are consistently eliminated.
*Aldosterone excess from obstructive sleep apnea persists despite CPAP*
- Effectively treated **OSA** typically leads to a reduction in **aldosterone levels** because it removes the stimulus of intermittent hypoxia and **RAAS activation**.
- If **CPAP** therapy is effective and adherent, any remaining **aldosterone excess** would likely be due to a primary adrenal pathology rather than the **OSA** itself.
